Log in

Relevant bibliographies by topics / Dose to medium / Journal articles

Journal articles on the topic 'Dose to medium'

To see the other types of publications on this topic, follow the link: Dose to medium.

Author: Grafiati

Published: 10 December 2022

Last updated: 29 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Dose to medium.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Fonseca, Gabriel Paiva, Åsa Carlsson Tedgren, Brigitte Reniers, Josef Nilsson, Maria Persson, Hélio Yoriyaz, and Frank Verhaegen. "Dose specification for192Ir high dose rate brachytherapy in terms of dose-to-water-in-medium and dose-to-medium-in-medium." Physics in Medicine and Biology 60, no. 11 (May 26, 2015): 4565–79. http://dx.doi.org/10.1088/0031-9155/60/11/4565.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Enger, Shirin A., Anders Ahnesjo, and Luc Beaulieu. "Dose to Medium or Dose to a Water Cavity Embedded in Medium?" Brachytherapy 9 (April 2010): S35. http://dx.doi.org/10.1016/j.brachy.2010.02.036.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Mahnke, N., K. Medve-Koenigs, M. Megahed, and N. J. Neumann. "Medium-dose-UV-A1-Phototherapie." Der Hautarzt 54, no. 4 (March 7, 2003): 364–66. http://dx.doi.org/10.1007/s00105-003-0503-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Enger, S. Abbasinejad, A. Ahnesjö, and L. Beaulieu. "682 poster DOSE TO MEDIUM OR DOSE TO A WATER CAVITY EMBEDDED IN MEDIUM?" Radiotherapy and Oncology 99 (May 2011): S273. http://dx.doi.org/10.1016/s0167-8140(11)70804-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Ma, C.-M., and Jinsheng Li. "Dose specification for radiation therapy: dose to water or dose to medium?" Physics in Medicine and Biology 56, no. 10 (April 20, 2011): 3073–89. http://dx.doi.org/10.1088/0031-9155/56/10/012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Leonardi, M. "Contrast medium dose and renal failure." Radiology 207, no. 3 (June 1998): 832–33. http://dx.doi.org/10.1148/radiology.207.3.9609917.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Enger, S. A., A. Ahnesjo, F. Verhaegen, and L. Beaulieu. "SU-E-T-07: Dose to Medium or Dose to a Water Cavity Embedded in Medium?" Medical Physics 38, no. 6Part10 (June 2011): 3487. http://dx.doi.org/10.1118/1.3611957.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Kowalzick, Lutz. "UVA1 for atopic dermatitis: Medium dose superior to low dose." Journal of the American Academy of Dermatology 44, no. 3 (March 2001): 548. http://dx.doi.org/10.1067/mid.2001.111343.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Kowalzick, Lutz. "UVA1 for atopic dermatitis: Medium dose superior to low dose." Journal of the American Academy of Dermatology 44, no. 3 (March 2001): 0548. http://dx.doi.org/10.1067/mjd.2001.111343.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Patel, Firuza D., Pritam S. Negi, Suresh C. Sharma, Rakesh Kapoor, Deepinder P. Singh, and Sushmita Ghoshal. "Dose rate correction in medium dose rate brachytherapy for carcinoma cervix." Radiotherapy and Oncology 49, no. 3 (December 1998): 317–23. http://dx.doi.org/10.1016/s0167-8140(98)00100-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Paganetti, Harald. "Dose to water versus dose to medium in proton beam therapy." Physics in Medicine and Biology 54, no. 14 (June 23, 2009): 4399–421. http://dx.doi.org/10.1088/0031-9155/54/14/004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Lan, Nguyen Thi Linh, and Do Thi Thu Hien. "COMPARISON OF LOW-DOSE AND MEDIUM-DOSE ORAL ISOTRETINOIN FOR TREATMENT OF ROSACEA." Tạp chí Da liễu học Việt Nam 35 (June 13, 2022): 20–27. http://dx.doi.org/10.56320/tcdlhvn.v35i.5.

Full text

Abstract:

Objectives: To compare the results of treatment of papulopustular rosacea by low-dose oral isotretinoin (0.15-0.25 mg/kg/day) and medium-dose (0.4-0.5 mg/kg/day). Subjects and methods: Randomized controlled clinical trial: 54 patients with papulopustular rosacea were randomly assigned to 2 groups: group 1 treated by low-dose oral isotretinoin and group 2 treated by medium-dose for 8 weeks. Results: After 8 weeks of treatment, the number of papules and pustules and erythema decreased clearly in both groups. The improvement of erythema by CEA score was similar in all patients treated by medium and low doses of isotretinoin (52.7% vs 45.4, p>0.05). The reduction of number of papules and pustules in patients with mild and moderate IGA score was not diferent between two groups treated by medium and low-dose oral isotretinoin. However, the reduction of number of papules and pustules in group with severe IGA score was significantly more rapidly when treated by medium-dose than low-dose oral isotretinoin (76.8 % vs 84.7%; p<0.05). Adverse events were observed only on the skin including dryness and irritation which were more frequent and severe in group treated by medium-doses compared to group treated by lose-dose oral isotretinoin. Conclusion: Isotretinoin is safe and effective in the treatment of papulopustular rosacea. The improvement of erythema, papules and pustules was similar in all patients treated by medium and low-dose of oral isotretinoin. However, the reduction of number of papules and pustules in severe IGA group was significantly more rapidly when treated by medium-dose than low-dose of oral isotretinoin at week 8th.

APA, Harvard, Vancouver, ISO, and other styles

13

Iezzi, Roberto, and Lorenzo Bonomo. "Low-Dose CT Angiography: Which Contrast Medium?" American Journal of Roentgenology 201, no. 4 (October 2013): W660. http://dx.doi.org/10.2214/ajr.13.10771.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Mahnke, Natalia, Kathrin Medve-Koenigs, Mark Berneburg, Thomas Ruzicka, and Norbert J. Neumann. "Cutaneous sarcoidosis treated with medium-dose UVA1." Journal of the American Academy of Dermatology 50, no. 6 (June 2004): 978–79. http://dx.doi.org/10.1016/j.jaad.2003.09.027.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Calzavara-Pinton, Piergiacomo, Marina Venturini, and Raffaella Sala. "Medium-dose UVA1 therapy of lymphomatoid papulosis." Journal of the American Academy of Dermatology 52, no. 3 (March 2005): 530–32. http://dx.doi.org/10.1016/j.jaad.2004.09.036.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Reynaert, N., F. Crop, E. Sterpin, and H. Palmans. "OC-0226: Towards consistency of TPS dose calculations: converting dose to medium to dose to water." Radiotherapy and Oncology 123 (May 2017): S112—S113. http://dx.doi.org/10.1016/s0167-8140(17)30669-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Walters, B. R. B., R. Kramer, and I. Kawrakow. "Dose to medium versus dose to water as an estimator of dose to sensitive skeletal tissue." Physics in Medicine and Biology 55, no. 16 (July 29, 2010): 4535–46. http://dx.doi.org/10.1088/0031-9155/55/16/s08.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

&NA;. "Low- vs medium-dose aspirin after coronary surgery." Inpharma Weekly &NA;, no. 1417 (December 2003): 17. http://dx.doi.org/10.2165/00128413-200314170-00037.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Efentaki, Pinelopi, Andreas Altenburg, Johannes Haerting, and Christos C. Zouboulis. "Medium-dose prednisolone pulse therapy in alopecia areata." Dermato-Endocrinology 1, no. 6 (November 2009): 311–14. http://dx.doi.org/10.4161/derm.1.6.11236.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Hermes, B., C. Praetel, and B. M. Henz. "Medium dose isotretinoin for the treatment of acne." Journal of the European Academy of Dermatology and Venereology 11, no. 2 (September 1998): 117–21. http://dx.doi.org/10.1111/j.1468-3083.1998.tb00763.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

George, P. J., J. M. Hadley, B. S. Mantell, and R. M. Rudd. "Medium dose rate endobronchial radiotherapy with caesium-137." Thorax 47, no. 6 (June 1, 1992): 474–77. http://dx.doi.org/10.1136/thx.47.6.474.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Munshi, A., F. D. Patel, S. C. Sharma, D. P. Singh, S. Ghoshal, T. S. Kehwar, and R. Kapoor. "Comparative evaluation of fractionated medium dose rate brachytherapy versus conventional single fraction medium dose rate in treatment of carcinoma cervix." International Journal of Radiation Oncology*Biology*Physics 51, no. 3 (November 2001): 328–29. http://dx.doi.org/10.1016/s0360-3016(01)02428-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Enger, S., A. Ahnesjo, and L. Beaulieu. "SU-GG-T-438: Dose to Medium or Dose to a Water Cavity Embedded in Medium? A Monte Carlo Study." Medical Physics 37, no. 6Part22 (June 2010): 3287. http://dx.doi.org/10.1118/1.3468836.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Yang, Xiaoyu, Ying Cao, Qigang Shao, Shuzhou Li, Mingjun Lei, and Zhen Yang. "Improving the accuracy of converting dose to medium to dose to water algorithms in small megavoltage photon fields in dose to medium based treatment planning systems." Physica Medica 71 (March 2020): 62–70. http://dx.doi.org/10.1016/j.ejmp.2020.01.024.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Leborgne, Felix, Jack F. Fowler, Jose H. Leborgne, Eduardo Zubizarreta, and Rick Chappell. "Biologically effective doses in medium dose rate brachytherapy of cancer of the cervix." Radiation Oncology Investigations 5, no. 6 (1997): 289–99. http://dx.doi.org/10.1002/(sici)1520-6823(1997)5:6<289::aid-roi5>3.0.co;2-u.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Delbaere, A., T. Younes, M. Chauvin, L. Simon, C. Khamphan, and L. Vieillevigne. "PD-0187: Converting absorbed dose-to-medium to dose-to-water in heterogeneous media." Radiotherapy and Oncology 152 (November 2020): S92—S93. http://dx.doi.org/10.1016/s0167-8140(21)00211-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Tzaneva, Stanislava, Arno Seeber, Martina Schwaiger, Herbert Hönigsmann, and Adrian Tanew. "High-dose versus medium-dose UVA1 phototherapy for patients with severe generalized atopic dermatitis." Journal of the American Academy of Dermatology 45, no. 4 (October 2001): 503–7. http://dx.doi.org/10.1067/mjd.2001.114743.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Pacifico, A., P. Iacovelli, G. Damiani, C. Ferraro, S. Cazzaniga, R. R. Z. Conic, G. Leone, and A. Morrone. "‘High dose’ vs. ‘medium dose’ UVA1 phototherapy in italian patients with severe atopic dermatitis." Journal of the European Academy of Dermatology and Venereology 33, no. 4 (December 28, 2018): 718–24. http://dx.doi.org/10.1111/jdv.15362.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Langendijk, J., J. Jager, J. de Jong, J. Rijken, and M. Pannebakker. "168 High dose rate versus medium dose rate intraluminal brachytherapy in inoperable esophageal carcinoma." Radiotherapy and Oncology 39 (May 1996): S42. http://dx.doi.org/10.1016/0167-8140(96)87970-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Siebers, J. V., P. J. Keall, A. E. Nahum, and R. Mohan. "Converting absorbed dose to medium to absorbed dose to water for Monte Carlo based photon beam dose calculations." Physics in Medicine and Biology 45, no. 4 (March 17, 2000): 983–95. http://dx.doi.org/10.1088/0031-9155/45/4/313.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Cabanas, Maria Lavin, Chenyu Yan, Ronald J. Lalonde, Dwight E. Heron, and M. Saiful Huq. "Which Dose Specification Should Be Used for NRG Radiation Therapy Trials: Dose-to-Medium or Dose-to-Water?" Practical Radiation Oncology 10, no. 2 (March 2020): e103-e110. http://dx.doi.org/10.1016/j.prro.2019.08.008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Cabanas, M., C. Yan, R. J. Lalonde, D. E. Heron, and S. Huq. "What Dose Specification Should be used for NRG Radiation Therapy Trials, Dose-to-Medium or Dose-to-Water?" International Journal of Radiation Oncology*Biology*Physics 102, no. 3 (November 2018): e531-e532. http://dx.doi.org/10.1016/j.ijrobp.2018.07.1492.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Satmoko, A., T. Harjanto, I. M. Putra, and Kristiyanti Kristiyanti. "The Preliminary Prototype of Medium Dose Rate Brachytherapy Equipment." Atom Indonesia 39, no. 2 (October 3, 2013): 75. http://dx.doi.org/10.17146/aij.2013.234.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Björk, L., and B. F. Zachrisson. "Low Dose Urography with a Low Osmolar Contrast Medium." Acta Radiologica. Diagnosis 27, no. 1 (January 1986): 111–13. http://dx.doi.org/10.1177/028418518602700122.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Peterström, S., and B. G. Svensson. "Transient boron diffusion in medium dose germanium‐implanted silicon." Journal of Applied Physics 71, no. 3 (February 1992): 1215–18. http://dx.doi.org/10.1063/1.351290.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Korniliosii, N., G. Marest, A. Pérez, M. Brunel, B. Gilles, Ph Gérard, and F. Ravel. "Medium and high dose iron implantations in various garnets." Nuclear Instruments and Methods in Physics Research Section B: Beam Interactions with Materials and Atoms 19-20 (January 1987): 860–64. http://dx.doi.org/10.1016/s0168-583x(87)80172-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Linden, Karl G., and Jeannie L. Darby. "Estimating Effective Germicidal Dose from Medium Pressure UV Lamps." Journal of Environmental Engineering 123, no. 11 (November 1997): 1142–49. http://dx.doi.org/10.1061/(asce)0733-9372(1997)123:11(1142).

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Beck, T. M., P. J. Hesketh, S. Madajewicz, R. M. Navari, K. Pendergrass, E. P. Lester, J. A. Kish, W. K. Murphy, J. D. Hainsworth, and D. R. Gandara. "Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting." Journal of Clinical Oncology 10, no. 12 (December 1992): 1969–75. http://dx.doi.org/10.1200/jco.1992.10.12.1969.

Full text

Abstract:

PURPOSE This study compares the efficacy and safety of two single-dose regimens with the approved three-dose regimen of ondansetron in the prevention of cisplatin-induced emesis. PATIENTS AND METHODS This multicenter study was a stratified, randomized, double-blind, and parallel group design. Chemotherapy-naive inpatients were randomized to receive intravenous (IV) ondansetron (Zofran; Glaxo Inc, Research Triangle Park, NC) 0.15 mg/kg times three doses, every 4 hours or a single 8-mg or 32-mg dose followed by two saline doses that began 30 minutes before cisplatin administration. Cisplatin (high-dose > or = 100 mg/m2 or medium-dose 50 to 70 mg/m2) was given as a single infusion (< or = 3 hours). Patients were monitored for emetic episodes, adverse events, and laboratory safety parameters for 24 hours after cisplatin administration. RESULTS A total of 699 patients (359 high-dose, 340 medium-dose) were enrolled. Of these, 618 were assessable for efficacy (15 ineligible, 66 protocol deviations). The 32-mg dose was superior to the 8-mg single dose with regard to total number of emetic episodes (high-dose, P = .015; medium-dose, P < .001), complete response (no emetic episodes: high-dose, 48% v 35%; P = .048; medium-dose, 73% v 50%; P = .001) and failure rate (> 5 emetic episodes, withdrawn or rescued: high-dose, 20% v 34%; P = .018; medium-dose, 9% v 23%; P = .005). The 32-mg single dose was also superior to the 0.15 mg/kg times three dose regimen with regard to total number of emetic episodes (medium-dose, P = .033) and failure rate (high-dose, 20% v 36%; P = .009; medium-dose, 9% v 22%; P = .011). Ondansetron was well tolerated. The most common adverse event was headache. An approximate 10-fold increase in the incidence of clinically significant transaminase elevations was observed in the high-dose versus medium-dose cisplatin strata (aspartate aminotransferase [AST], 6.5% v 0.7%; serum alanine aminotransferase [ALT], 5.0% v 0.3%). CONCLUSION A 32-mg single dose of ondansetron is more effective than a single 8-mg dose and is at least as effective as the standard regimen of 0.15 mg/kg times three doses in the prevention of cisplatin-induced acute emesis.

APA, Harvard, Vancouver, ISO, and other styles

39

Nithiyanantham, Karthikeyan, Ganesh K. Mani, Sambasivaselli Raju, Senniandavar Velliangiri, Maniyan Paramasivam, Karrthick K. Palaniappan, and Sandeep Jain. "Characterisation of small photon field outputs in a heterogeneous medium using X-ray voxel Monte Carlo dose calculation algorithm." Journal of Radiotherapy in Practice 17, no. 1 (August 23, 2017): 114–23. http://dx.doi.org/10.1017/s1460396917000498.

Full text

Abstract:

AbstractAimTo characterise small photon beams using the Monte Carlo dose calculation algorithm for small field ranges in a heterogeneous medium.Materials and methodAn in-house phantom constructed with three different mediums, foam, polymethyl methacrylate and delrin resembling the densities of lung, soft tissue and bone respectively, was used in this study. Photon beam energies of 6 and 15 MV and field sizes of 8×8, 16×16, 24×24, 32×32 and 40×40 mm using X-ray voxel Monte Carlo (XVMC) algorithm using different detectors were validated. The relative output factor was measured in three different mediums having six different tissue interfaces; at the depth of 0, 1, 2 and 3 cm. The planar dose verification was undertaken using gafchromic films and considered dose at the lung and bone medium interfaces. For all the measurements, 104×104 mm was taken as the reference field size. The relative output factor for all other field sizes was taken and compared with planning system calculated values.ResultsFrom field size 16×16 mm and above, the relative output factors were analysed in bone and soft tissue medium having lung as first medium. The maximum deviations were observed as 1·8 and 1·3% for 6 MV and 2·5 and 1·1% for 15 MV photon beams for bone and soft tissue, respectively. For lung as measurement medium, the maximum deviation of 14·8 and 19·2% were observed and having bone as first medium with 8×8 mm for 6 and 15 MV photon beams, respectively. The fluence verification of dose spectrum for the lung–bone interface scenarios with smaller field sizes were found within 2% of deviation with treatment planning system (TPS).ConclusionThe accuracy of dose calculations for small field sizes in XVMC-based treatment planning algorithm was studied in different inhomogeneous mediums. It was found that the results correlated with measurement data for field size 16×16 mm and above. Noticeable deviation was observed for the smallest field size of 8×8 mm with interfaces of significant change in density. The observed results demands further analysis of work with smaller field sizes.

APA, Harvard, Vancouver, ISO, and other styles

40

Paganetti, H. "SU-FF-T-405: Dose to Water Versus Dose to Medium in Proton Beam Therapy." Medical Physics 36, no. 6Part15 (June 2009): 2615. http://dx.doi.org/10.1118/1.3181887.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

YOKOYAMA, T., F. YAMASAKI, K. YAMASHITA, M. MANABE, and K. SUWA. "Bleeding time prolonged by daily low-dose aspirin is shortened by one medium dose aspirin." Acta Anaesthesiologica Scandinavica 52, no. 9 (September 12, 2008): 1226–30. http://dx.doi.org/10.1111/j.1399-6576.2008.01766.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Adli, M., Ch Baethge, A. Heinz, N. Langlitz, and M. Bauer. "Is dose escalation of antidepressants a rational strategy after a medium–dose treatment has failed?" European Archives of Psychiatry and Clinical Neuroscience 255, no. 6 (April 29, 2005): 387–400. http://dx.doi.org/10.1007/s00406-005-0579-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Yang, Zhe, Rui Zhao, and Wangjun Gao. "The effects of curcumin on the biological behavior of colorectal cancer cells through the JAK/STAT3 and RAS/MAPK/NF-κB pathways." Investigación Clínica 63, no. 4 (November 11, 2022): 353–62. http://dx.doi.org/10.54817/ic.v63n4a03.

Full text

Abstract:

The purpose of this work was to investigate the effects of curcumin on the biological behavior of colorectal cancer cells through the JAK/STAT3 and RAS/MAPK/NF-κB pathways. Human colorectal cancer HCT116 cells were cultured and divided into a control group and low, medium and high-dose curcumin groups (n =5). HCT116 colorectal cancer cells became long-growing cells after incubation and culture at 37°C. The control group was treated with 15μL phosphate-buffered saline, and the low-dose, medium-dose and high-dose curcumin groups were treated with 20, 40 and 80μmol/L curcumin, respectively. All groups were treated with rel-evant drug intervention, digested and centrifuged for 48h, washed twice with a PBS solution, centrifuged at 1000 rpm for 3 min, and the cells precipitated. The prolif-eration, apoptosis and growth cycle of cells in each group were observed, and the ex-pressions of the JAK/STAT3 and RAS/MAPK/NF-κB pathways and related proteins in each group were studied. Compared with the curcumin low-dose and medium-dose groups, the proliferation ability of the curcumin high-dose group was significantly decreased (P<0.05). When the low-dose and medium-dose curcumin groups were compared with the high-dose curcumin group, the apoptosis ability was significantly increased (P<0.05). When the low-dose and medium-dose curcumin groups were compared, the growth ratio of the G0/G1 phase in the high-dose curcumin group was significantly increased, and the percentage of the S phase was significantly de-creased (P<0.05). Compared with the curcumin low-dose and medium-dose groups, the expression of JAK-STAT3 and RAS/MAPK/NF-κB pathway in the curcumin high-dose group was significantly decreased (P<0.05). The protein expressions of STAT3, RAS, P-P38 and P65 in the curcumin high-dose group were significantly lower than those in the curcumin low-dose and medium-dose groups (P<0.05). Curcumin can inhibit the expression of JAK/STAT3 and RAS/MAPK/NF-κB pathways, block the growth cycle, and inhibit the proliferation and induce apoptosis of colorectal cancer cells, providing a new idea for the clinical treatment of colorectal cancer.

APA, Harvard, Vancouver, ISO, and other styles

44

Szpala, Stanislaw, James Renaud, Bryan R. Muir, Alexandra Bourgouin, Kirpal Kohli, and Malcolm McEwen. "Calorimeter measurements of absolute dose in aluminum, a surrogate of bone, to validate dose-to-medium in Acuros XB." Physics in Medicine & Biology 68, no. 1 (December 29, 2022): 015019. http://dx.doi.org/10.1088/1361-6560/aca869.

Full text

Abstract:

Abstract Objective. While the accuracy of dose calculations in water with Acuros XB is well established, experimental validation of dose in bone is limited. Acuros XB reports both dose-to-medium and dose-to-water, and these values differ in bone, but there are no reports of measurements of validation in bone. This work compares Acuros XB calculations to measurements of absolute dose in aluminum (medium similar to bone). The validity of using selected relative dosimeters in aluminum is also investigated. Approach. A calorimeter with an aluminum core embedded in an aluminum phantom was selected as bone surrogate for the measurement of absolute dose. Matching the medium of the core to the medium of the phantom allowed eliminating the calculation of the conversion between media. The dose was measured at the fixed depth of 3.3 cm in aluminum (∼9 g·cm−2) with 6X, 10X, 6FFF and 10FFF photon beams from a TrueBeam Varian linac. In addition, experimental cross-calibration between water and aluminum was performed for an IBA CC13 ionization chamber, a PTW microDiamond and EBT3 Gafchromic film. Main results. Calculations with Acuros XB dose-to-medium in aluminum differed from the calorimetry data by −2.8% to −3.5%, depending on the beam. Use of dose-to-water would have resulted in about 39% discrepancy. The cross calibration coefficient between water and aluminum yielded values of about 0.87 for the CC13 chamber, 0.91 for the microDiamond, and 0.88 for the film, and independent of the beam within about ±1%. Significance. It was demonstrated the value of the dose-to-medium in aluminum (surrogate of bone) computed with Acuros XB is close to the value of the absolute dose measured with a calorimeter, and there is a significant discrepancy when dose-to-water is used instead. The use of an ionization chamber, a microDiamond and Gafchromic film in aluminum required a considerable correction from calibration in water.

APA, Harvard, Vancouver, ISO, and other styles

45

Agarwal, Ritesh, Ashutosh N. Aggarwal, Sahajal Dhooria, Inderpaul Singh Sehgal, Mandeep Garg, Biman Saikia, Digambar Behera, and Arunaloke Chakrabarti. "A randomised trial of glucocorticoids in acute-stage allergic bronchopulmonary aspergillosis complicating asthma." European Respiratory Journal 47, no. 2 (November 19, 2015): 490–98. http://dx.doi.org/10.1183/13993003.01475-2015.

Full text

Abstract:

Whether use of high-dose steroids in acute-stage allergic bronchopulmonary aspergillosis (ABPA) is associated with superior outcomes is not known. Herein, we compare the efficacy and safety of two glucocorticoid protocols in ABPA.Treatment-naive ABPA subjects randomly received either high-dose or medium-dose oral prednisolone. The primary outcomes were exacerbation rates and glucocorticoid-dependent ABPA after 1 and 2 years, respectively, of treatment. The secondary end-points were composite response rates after 6 weeks, improvement in lung function, time to first exacerbation, cumulative dose and adverse effects.92 subjects (high-dose n=44, medium-dose n=48) were included in the study. The numbers of subjects with exacerbation after 1 year (high-dose 40.9% versus medium-dose 50%, p=0.59) and glucocorticoid-dependent ABPA after 2 years (high-dose 11.4% versus medium-dose 14.6%, p=0.88) were similar in the two groups. Although composite response rates were significantly higher in the high-dose group, improvement in lung function and time to first exacerbation were similar in the two groups. Cumulative glucocorticoid dose and side-effects were significantly higher in the high-dose group.Medium-dose oral glucocorticoids are as effective and safer than high-dose in treatment of ABPA.

APA, Harvard, Vancouver, ISO, and other styles

46

Gärtner, R., G. Bechtner, D. Stübner, and W. Greil. "Paracrine interaction between thyrocytes and fibroblasts." Acta Endocrinologica 116, no. 1_Suppl (August 1987): S225—S230. http://dx.doi.org/10.1530/acta.0.114s225.

Full text

Abstract:

Abstract. Cell free supernatants (conditioned medium) of isolated porcine thyroid follicles, stimulated with EGF (5 ng/ml) or TSH (1–1000 μU/ml), were tested for a mitogenic activity for fibroblasts. Whereas TSH-conditioned medium dose-dependently stimulated [3H]thymidine incorporation into DNA of fibroblasts, only a weak stimulation was found with EGF. However, when the changes in cell number were determined, a significant increase was only found with EGF-conditioned medium from thyroid follicles. The cause of this discrepancy is a dose-dependent stimulation of [3H]thymidine incorporation into fibroblasts by cAMP and thyroid hormones. Cyclic AMP, however, does not stimulate growth of fibroblasts. IGF I production is stimulated in fibroblasts by basal as well as EGF stimulated conditioned medium of thyroid follicles. In contrast, TSH-conditioned medium inhibited IGF I production in fibroblasts. Conditioned medium itself is free of detectable IGF I. As IGF I stimulates not only growth of fibroblasts, but also of thyrocytes, we conclude, that conditioned medium from thyrocytes stimulates IGF I production in fibroblasts, which itself stimulates fibroblast and thyrocyte growth.

APA, Harvard, Vancouver, ISO, and other styles

47

Rahman, Tasmina, Md Rakib Hasan, and MSK Choudhuri. "Effect of Ashwagandharista (Withania somnifera) on the kidney functions of male and female rats." Jahangirnagar University Journal of Biological Sciences 8, no. 1 (August 3, 2019): 1–7. http://dx.doi.org/10.3329/jujbs.v8i1.42462.

Full text

Abstract:

The key objective of this present study was to analyze the effect(s) of Ashwagandharishta on the kidney functions of both male and female Albino rats. Chronic toxicity tests were also done. Following treatments the rats were observed for 51 days to know the effects of Ashwagandharishta on kidney functions considering 3 parameters such as serum urea, creatinine and uric acid. Our results failed to exhibit a significant increase in serum urea level at low dose (P<0.01), medium dose (P<0.05) and at high dose (P<0.001) in male rat groups; but with female rat groups our results showed significant increase in serum urea level at three dose levels. Regarding serum creatinine level male rats and female rats showed a trend of increase in level at different dose but effects were insignificant except medium dose in male rats (P<0.05). Regarding serum uric acid level our results failed to show a significant increase irrespective of dose. Jahangirnagar University J. Biol. Sci. 8(1): 1-7, 2019 (June)

APA, Harvard, Vancouver, ISO, and other styles

48

KASHANI, Iraj A., Sarah S. HIGGINS, William GRISWOLD, Richard E. SWENSSON, and Charles B. HIGGINS. "Renal function in children after large dose contrast medium angiocardiography." Japanese Heart Journal 26, no. 3 (1985): 451–56. http://dx.doi.org/10.1536/ihj.26.451.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Su, Ozlem, Nahide Onsun, Hulya Kapran Onay, Yeliz Erdemoglu, Dilek Biyik Ozkaya, Filiz Cebeci, and Adnan Somay. "Effectiveness of medium-dose ultraviolet A1 phototherapy in localized scleroderma." International Journal of Dermatology 50, no. 8 (July 22, 2011): 1006–13. http://dx.doi.org/10.1111/j.1365-4632.2010.04843.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Haghmorad, Dariush, Zohreh Salehipour, Reza Nosratabadi, Maryam Rastin, Parviz Kokhaei, Mohammad Bagher Mahmoudi, Abbas Ali Amini, and Mahmoud Mahmoudi. "Medium-dose estrogen ameliorates experimental autoimmune encephalomyelitis in ovariectomized mice." Journal of Immunotoxicology 13, no. 6 (September 7, 2016): 885–96. http://dx.doi.org/10.1080/1547691x.2016.1223768.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!